Cannabis Poland Past Earnings Performance

Past criteria checks 0/6

Cannabis Poland's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 6.5% per year.

Key information

-9.0%

Earnings growth rate

14.5%

EPS growth rate

Pharmaceuticals Industry Growth29.4%
Revenue growth rate6.5%
Return on equity-40.0%
Net Margin-686.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cannabis Poland makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:CBD Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-220
30 Jun 240-120
31 Mar 240-110
31 Dec 230-110
30 Sep 230-110
30 Jun 230-110
31 Mar 230-110
31 Dec 220-110
30 Sep 220-110
30 Jun 220-110
31 Mar 220-110
31 Dec 210-110
30 Sep 210-110
30 Jun 210-110
31 Mar 210-110
31 Dec 200-110
30 Sep 200-110
30 Jun 200-110
31 Mar 200-100
31 Dec 190000
30 Sep 190-200
30 Jun 190-400
31 Mar 190-100
31 Dec 180-400
30 Sep 180-300
30 Jun 180-100
31 Mar 180-100
31 Dec 170-100
30 Sep 171-110
30 Jun 171-120
31 Mar 172-120
31 Dec 163-130
30 Sep 164030
30 Jun 164040
31 Mar 164030
31 Dec 154030
30 Sep 154030
30 Jun 154030
31 Mar 154030
31 Dec 144030
30 Sep 143020
30 Jun 143120
31 Mar 143120
31 Dec 133120

Quality Earnings: CBD is currently unprofitable.

Growing Profit Margin: CBD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CBD is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare CBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: CBD has a negative Return on Equity (-39.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 12:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cannabis Poland S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution